Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Araujo

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Cancer Management and Research|March 22, 2013
Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxelJohn C Araujo, Geralyn C Trudel, Prashni Paliwal
Cancer Metastasis Reviews|February 14, 2014
Src signaling pathways in prostate cancerAndreas Varkaris, Anastasia D Katsiampoura, John C Araujo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 13, 2015
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall SurvivalElba C Etchebehere, John C Araujo, Patricia S Fox, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 30, 2015
Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institutionElba C Etchebehere, Denái R Milton, John C Araujo, et al.
The Prostate|February 2, 2013
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancerFarshid Dayyani, Andreas Varkaris, John C Araujo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2015
Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CTEric M Rohren, Elba C Etchebehere, John C Araujo, et al.
The Prostate|April 2, 2011
Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profilesAna Aparicio, Vasiliki Tzelepi, John C Araujo, et al.
Cancer Biology & Therapy|October 27, 2009
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formationJohn C Araujo, Ann Poblenz, Paul Corn, et al.
BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.
American Journal of Clinical Oncology|June 19, 2012
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinomaStephen L Richey, Pheroze Tamboli, Chaan S Ng, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Cancer Management and Research|March 22, 2013
Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxelJohn C Araujo, Geralyn C Trudel, Prashni Paliwal
Cancer Metastasis Reviews|February 14, 2014
Src signaling pathways in prostate cancerAndreas Varkaris, Anastasia D Katsiampoura, John C Araujo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 13, 2015
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall SurvivalElba C Etchebehere, John C Araujo, Patricia S Fox, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 30, 2015
Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institutionElba C Etchebehere, Denái R Milton, John C Araujo, et al.
The Prostate|February 2, 2013
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancerFarshid Dayyani, Andreas Varkaris, John C Araujo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2015
Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CTEric M Rohren, Elba C Etchebehere, John C Araujo, et al.
The Prostate|April 2, 2011
Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profilesAna Aparicio, Vasiliki Tzelepi, John C Araujo, et al.
Cancer Biology & Therapy|October 27, 2009
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formationJohn C Araujo, Ann Poblenz, Paul Corn, et al.
BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.
American Journal of Clinical Oncology|June 19, 2012
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinomaStephen L Richey, Pheroze Tamboli, Chaan S Ng, et al.
Pageof 4